Amir Ashoorzadeh

652 total citations
32 papers, 476 citations indexed

About

Amir Ashoorzadeh is a scholar working on Molecular Biology, Cancer Research and Biotechnology. According to data from OpenAlex, Amir Ashoorzadeh has authored 32 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Cancer Research and 10 papers in Biotechnology. Recurrent topics in Amir Ashoorzadeh's work include Cancer, Hypoxia, and Metabolism (16 papers), Cancer Research and Treatments (10 papers) and Nanoplatforms for cancer theranostics (6 papers). Amir Ashoorzadeh is often cited by papers focused on Cancer, Hypoxia, and Metabolism (16 papers), Cancer Research and Treatments (10 papers) and Nanoplatforms for cancer theranostics (6 papers). Amir Ashoorzadeh collaborates with scholars based in New Zealand, United Kingdom and Netherlands. Amir Ashoorzadeh's co-authors include Adam V. Patterson, Jeff B. Smaill, Christopher P. Guise, Alexandra M. Mowday, Ke Ding, David F. Ackerley, Wanhua Lin, Ran Yuan, William A. Denny and Elsie M. Williams and has published in prestigious journals such as Angewandte Chemie International Edition, Blood and Biochemistry.

In The Last Decade

Amir Ashoorzadeh

32 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amir Ashoorzadeh New Zealand	11	241	149	110	100	92	32	476
Dianne M. Ferry New Zealand	10	263 1.1×	203 1.4×	79 0.7×	89 0.9×	85 0.9×	12	562
Sophie P. Syddall New Zealand	7	257 1.1×	147 1.0×	74 0.7×	146 1.5×	38 0.4×	12	438
Maria R. Abbattista New Zealand	9	235 1.0×	198 1.3×	78 0.7×	72 0.7×	33 0.4×	28	415
Alexandra M. Mowday New Zealand	12	342 1.4×	261 1.8×	205 1.9×	203 2.0×	57 0.6×	22	766
Peter A. Harris United Kingdom	11	293 1.2×	123 0.8×	88 0.8×	125 1.3×	40 0.4×	19	587
Hiu‐Chi Chong Hong Kong	7	236 1.0×	75 0.5×	34 0.3×	151 1.5×	133 1.4×	8	471
Dixy E. Green United States	16	430 1.8×	80 0.5×	61 0.6×	35 0.3×	188 2.0×	27	659
Wenqi Jiang China	14	395 1.6×	128 0.9×	130 1.2×	87 0.9×	25 0.3×	22	796
Tomoaki Takakura Japan	11	233 1.0×	63 0.4×	43 0.4×	224 2.2×	35 0.4×	11	489
Marie Bobowski France	12	640 2.7×	72 0.5×	42 0.4×	57 0.6×	119 1.3×	15	815

Countries citing papers authored by Amir Ashoorzadeh

Since Specialization

Citations

This map shows the geographic impact of Amir Ashoorzadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Ashoorzadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Ashoorzadeh more than expected).

Fields of papers citing papers by Amir Ashoorzadeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amir Ashoorzadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Ashoorzadeh. The network helps show where Amir Ashoorzadeh may publish in the future.

Co-authorship network of co-authors of Amir Ashoorzadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Amir Ashoorzadeh. A scholar is included among the top collaborators of Amir Ashoorzadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amir Ashoorzadeh. Amir Ashoorzadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, M. İhsan, et al.. (2024). Synthesis of new 4-aminobenzoic acid (PABA) hydrazide-hydrazone/sulfonate hybrids and antimicrobial evaluation with ascorbic acid/salicylic acid/ N -acetyl cysteine combinations. Phosphorus, sulfur, and silicon and the related elements. 199(4). 316–323. 2 indexed citations

Ashoorzadeh, Amir, Alexandra M. Mowday, Christopher P. Guise, et al.. (2022). Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals. 15(2). 185–185. 3 indexed citations

Liu, Emily, Amir Ashoorzadeh, Gib Bogle, et al.. (2022). Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling. Frontiers in Pharmacology. 13. 803602–803602. 3 indexed citations

Singleton, Dean C., Alexandra M. Mowday, Christopher P. Guise, et al.. (2021). Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit. Cancer Gene Therapy. 29(7). 1021–1032. 6 indexed citations

Abbattista, Maria R., Amir Ashoorzadeh, Christopher P. Guise, et al.. (2021). Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3. Pharmaceuticals. 14(12). 1231–1231. 7 indexed citations

Mowday, Alexandra M., Janine N. Copp, Sophie P. Syddall, et al.. (2020). E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics. 10(23). 10548–10562. 21 indexed citations

Sharrock, Abigail V., et al.. (2020). Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug. Biotechnology Letters. 43(1). 203–211. 1 indexed citations

Niemans, Raymon, Ala Yaromina, Jan Theys, et al.. (2018). EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug. Radiotherapy and Oncology. 127. S1283–S1284. 1 indexed citations

Li, Xueqiang, Christopher P. Guise, Y. Yosaatmadja, et al.. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry. 135. 531–543. 24 indexed citations

10.

Copp, Janine N., Alexandra M. Mowday, Elsie M. Williams, et al.. (2017). Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy. Cell chemical biology. 24(3). 391–403. 56 indexed citations

11.

Cavazos, Antonio, Helen Ma, Juliana M. Benito, et al.. (2016). Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML. Blood. 128(22). 5210–5210. 1 indexed citations

12.

Mowday, Alexandra M., Amir Ashoorzadeh, Elsie M. Williams, et al.. (2016). Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. Biochemical Pharmacology. 116. 176–187. 17 indexed citations

13.

Lu, Guo‐Liang, Amir Ashoorzadeh, Robert F. Anderson, Adam V. Patterson, & Jeff B. Smaill. (2013). Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966. Tetrahedron. 69(43). 9130–9138. 4 indexed citations

14.

Prosser, Gareth A., Janine N. Copp, Alexandra M. Mowday, et al.. (2013). Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochemical Pharmacology. 85(8). 1091–1103. 43 indexed citations

15.

Stevenson, Ralph J., William A. Denny, Moana Tercel, Frederik B. Pruijn, & Amir Ashoorzadeh. (2012). Nitro seco Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated Prodrugs for Cancer Therapy. Journal of Medicinal Chemistry. 55(6). 2780–2802. 23 indexed citations

16.

Ashoorzadeh, Amir, Graham J. Atwell, Frederik B. Pruijn, et al.. (2011). The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins. Bioorganic & Medicinal Chemistry. 19(16). 4851–4860. 7 indexed citations

17.

Smaill, Jeff B., Jagdish K. Jaiswal, Maria R. Abbattista, et al.. (2011). Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.. Molecular Cancer Therapeutics. 10(11_Supplement). A247–A247. 3 indexed citations

18.

Tercel, Moana, Graham J. Atwell, Shangjin Yang, et al.. (2011). Selective Treatment of Hypoxic Tumor Cells In Vivo: Phosphate Pre‐Prodrugs of Nitro Analogues of the Duocarmycins. Angewandte Chemie International Edition. 50(11). 2606–2609. 39 indexed citations

19.

Stevenson, Ralph J., et al.. (2011). The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy. Bioorganic & Medicinal Chemistry. 19(20). 5989–5998. 4 indexed citations

20.

Ashoorzadeh, Amir & Vittorio Caprio. (2005). A Convergent Enantioselective Synthesis of the Antimalarial Agent (+)‐Febrifugine.. ChemInform. 36(29). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact